Business
Cardiol Therapeutics Reports Results of its AGM
Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Reports Results of its AGMOakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting (\"AGM\") of shareholders held in Toronto, Ontario, on June 12, 2019. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.Resolutions proposed and approved at the AGM are:The re-election of the following directors for the ensuing year: David Elsley, Dr. Eldon Smith, Deborah Brown, Iain Chalmers, Terry Lynch, Peter Pekos, Dr. Guillermo Torre-AmioneThe appointment of BDO Canada LLP as auditors of the Company until the next annual meeting and the authorization of the directors of the Corporation to fix the remuneration to be paid to the auditorsThe results of the voting on the election of directors are as follows:NomineesNumber of Shares ForPercentage of Votes Cast ForDavid Eisley 12,461,59499.93%Dr. Eldon R. Smith 12,461,69499.93%Deborah Brown 12,468,77999.99%Iain Chalmers12,461,59499.93%Terry Lynch12,461,69499.93%Peter Pekos12,461,19499.93%Dr. Guillermo Torre-Amione12,468,27999.99% The corporate update delivered at the AGM by David Elsley, President and CEO, and Iain Chalmers, Chief Marketing Officer, is available for viewing on the Company's website at https://www.cardiolrx.com/investors/agmAbout Cardiol TherapeuticsCardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF) is a leader in producing 100% pure pharmaceutical CBD and developing groundbreaking therapies for heart disease. The Company is focused on commercially launching the safest and most consistent CBD products for consumers and healthcare providers in the multi-billion-dollar medicinal cannabinoid markets. Cardiol is utilizing nanotechnologies designed to deliver CBD and other anti-inflammatory drugs for the treatment of heart failure. Heart failure is a leading cause of death and hospitalization in North America, with associated healthcare costs exceeding US$30 billion annually in the U.S. alone. For further information about Cardiol, please visit the Company's website at www.cardiolrx.com. For further information, please contact:David Elsley, President & CEO9...